| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10019312 | HBV | ENSG00000182793.12 | protein_coding | GSTA5 | No | No | 221357 | Q7RTV2 |
| TVIS20018112 | HPV | ENSG00000182793.12 | protein_coding | GSTA5 | No | No | 221357 | Q7RTV2 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GSTA5 |
|---|---|
| DrugBank ID | DB00143 |
| Drug Name | Glutathione |
| Target ID | BE0000813 |
| UniProt ID | Q7RTV2 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 10085232; 9331086; 12076520 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@McDonagh PD, Judah DJ, Hayes JD, Lian LY, Neal GE, Wolf CR, Roberts GC: Determinants of specificity for aflatoxin B1-8,9-epoxide in alpha-class glutathione S-transferases. Biochem J. 1999 Apr 1;339 ( Pt 1):95-101.@@McLeod R, Ellis EM, Arthur JR, Neal GE, Judah DJ, Manson MM, Hayes JD: Protection conferred by selenium deficiency against aflatoxin B1 in the rat is associated with the hepatic expression of an aldo-keto reductase and a glutathione S-transferase subunit that metabolize the mycotoxin. Cancer Res. 1997 Oct 1;57(19):4257-66.@@Kazi S, Ellis EM: Expression of rat liver glutathione-S-transferase GSTA5 in cell lines provides increased resistance to alkylating agents and toxic aldehydes. Chem Biol Interact. 2002 May 20;140(2):121-35. |
| Groups | Approved; Investigational; Nutraceutical |
| Direct Classification | Peptides |
| SMILES | N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O |
| Pathways | Arachidonic Acid Metabolism; Flurbiprofen Action Pathway; 4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency; Oxaprozin Action Pathway; Rofecoxib Action Pathway; Pyruvate Kinase Deficiency; Acetaminophen Metabolism Pathway; Mefenamic Acid Action Pathway; Bromfenac Action Pathway; 5-Oxoprolinuria; gamma-Glutamyltransferase Deficiency; Naproxen Action Pathway; Sulindac Action Pathway; Glutathione Synthetase Deficiency; Piroxicam Action Pathway; Nabumetone Action Pathway; 2-Hydroxyglutric Aciduria (D and L Form); Meloxicam Action Pathway; Cyclophosphamide Action Pathway; Succinic Semialdehyde Dehydrogenase Deficiency; Valdecoxib Action Pathway; Ketorolac Action Pathway; 5-Oxoprolinase Deficiency; Acetylsalicylic Acid Action Pathway; Antipyrine Action Pathway; Glutathione Metabolism; Diclofenac Action Pathway; Homocarnosinosis; Cyclophosphamide Metabolism Pathway; Nepafenac Action Pathway |
| PharmGKB | PA449780 |
| ChEMBL | CHEMBL1543 |
